Thelansis

  Hemolytic-uremic syndrome (HUS) is a group of diseases characterized by the triad of nonimmune, microangiopathic hemolytic anemia, thrombocytopenia, and decreased renal function. The first injury is to the endothelium (mainly renal), causing cell swelling and later detachment, leading to the formation of thrombocyte aggregates, microthrombi, mechanical hemolytic anemia, and organ dysfunction, mainly of the kidneys and brain. Different primary triggers cause the different types of Hemolytic-uremic syndrome (HUS). The pathophysiology underlying the initial endothelial damage is diverse, as are the various epidemiologies, disease course, recurrence risks, treatments, and prognoses. This leads to the pathological lesion termed thrombotic microangiopathy, which mainly affects the kidney and other organs. Although the underlying cause may differ, HUS is associated with endothelial cell injury and platelet activation. The majority of HUS is associated with gastrointestinal infection w...

 Hemolytic-uremic syndrome (HUS) is a group of diseases characterized by the triad of nonimmune, microangiopathic hemolytic anaemia, thrombocytopenia, and decreased renal function. The first injury is to the endothelium (mainly renal), causing cell swelling and later detachment, leading to the formation of thrombocyte aggregates, microthrombi, mechanical hemolytic anemia, and organ dysfunction, mainly of the kidneys and brain. Different primary triggers cause the different types of Hemolytic-uremic syndrome (HUS). The pathophysiology underlying the initial endothelial damage is diverse, as are the various epidemiologies, disease course, recurrence risks, treatments, and prognoses. This leads to the pathological lesion termed thrombotic microangiopathy, which mainly affects the kidney and other organs. Although the underlying cause may differ, HUS is associated with endothelial cell injury and platelet activation. The majority of HUS is associated with gastrointestinal infection wit...